EUVIMEDEUVIMED entdecken
Crossref

Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly—Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying

Henry P Parkman, Daniel S Rim, Jonathan R Anolik, Simin Dadparvar, Alan H Maurer

Journal of Nuclear Medicine Technology · 2024-03 · 52 (1) · 3-7

DOI: 10.2967/jnmt.123.266800 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine Technology, online erschienen am 09.01.2024. Verfasst von Henry P Parkman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Section, Endocrinology and Metabolism Section, and Nuclear Medicine Section, Lewis Katz School of Medicine at Temple University, Phi…. Hauptthemen laut MEDLINE: Gastroparesis, Diabetes Mellitus. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagonlike peptide-1 (GLP-1) receptor agonists (RAs) are being increasingly used for glycemic control in patients with diabetes and for weight loss and weight management in obese subjects. There has been recent public awareness of the potential of GLP-1 RAs to delay gastric emptying and cause gastroparesis. By delaying gastric emptying, these agents can complicate the clinical evaluation of patients on these drugs by affecting diagnostic testing for gastroparesis. This article discusses GLP-1 RAs and their effects on gastric emptying, gastric food retention, and gastroparesis. This article highlights how physicians should be attuned to the gastric side effects of these popular therapeutic agents for blood glucose control in people with diabetes and for weight loss and weight management in obese patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GastroparesisDiabetes MellitusHumansGastric EmptyingBlood GlucoseWeight LossObesityPeptidesGlucagon-Like Peptide 1

Stichwörter der Autor:innen

GLP-1 receptor agonistsgastric emptying scintigraphygastroparesis

Substanzen

Blood GlucosePeptidesGlucagon-Like Peptide 1

Autor:innen und Institutionen

  • Gastroenterology Section, Endocrinology and Metabolism Section, and Nuclear Medicine Section, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania henry.parkman@temple.edu.
  • Gastroenterology Section, Endocrinology and Metabolism Section, and Nuclear Medicine Section, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.

Zitieren

APA

Parkman, H. P., Rim, D. S., Anolik, J. R., Dadparvar, S., & Maurer, A. H. (2024). Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly—Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying. Journal of Nuclear Medicine Technology, 52(1), 3-7. https://doi.org/10.2967/jnmt.123.266800

Vancouver

Parkman HP, Rim DS, Anolik JR, Dadparvar S, Maurer AH. Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly—Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying. Journal of Nuclear Medicine Technology. 2024;52(1):3-7. doi:10.2967/jnmt.123.266800

BibTeX
@article{Parkman2024,
  author = {Parkman, Henry P and Rim, Daniel S and Anolik, Jonathan R and Dadparvar, Simin and Maurer, Alan H},
  title = {Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly—Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying},
  journal = {Journal of Nuclear Medicine Technology},
  year = {2024},
  volume = {52},
  number = {1},
  pages = {3--7},
  doi = {10.2967/jnmt.123.266800}
}
Kostenlos starten →